EGFR and non-small cell lung carcinoma: Finally, targeted therapy is moving to the curative setting, with trials such as ADAURA showing a disease-free survival benefit among patients with resected stage IB-IIIA EGFR-mutation-positive NSCLC treated with adjuvant osimertinib [64].